Abstract
The initial metabolism of ifosfamide (IF) consists of two different pathways: enzymatic hydroxylation at carbon-4 forms the cytostatically active metabolite 4-OH-IF (“activated ifosfamide”) whereas side-chain oxidation results in the liberation of chloroacetaldehyde, a compound with possible neurotoxic properties. The pharmacokinetics of ifosfamide and its activated form were investigated in 12 cancer patients, who received both oral and i.v. treatment in a randomized sequence on days 1 and 3 at a dose of 1 g/m2 (n=7) or 1.5 g/m2 (n=5). In 3 patients the pharmacokinetics of chloroacetaldehyde were also investigated. After oral application, ifosfamide absorption proceeded rapidly, the oral bioavailability was 0.92. Independent of the route of ifosfamide application on day 1, the terminal half-life on day 3 (when the drug was given by the alternative route) was decreased in 6 out of the 12 patients, thus indicating self-induction of hepatic metabolism. 4-OH-IF was already present 20 min after ifosfamide administration. In the individual patient the concentrations of 4-OH-IF were always higher after oral than after i.v. IF application: the mean p.o.:i.v. ratios forc max and the area under the concentration/time curve were 2.3 and 1.7 respectively (P<0.05). In a first series of 3 patients the chloroacetaldehyde concentrations measured after oral ifosfamide application were about twice as high as those when the drug was given intravenously. These results indicate that (in comparison to the i.v. route) orally administered ifosfamide may be more cancerotoxic but also leads to higher levels of chloroacetaldehyde. This would explain the neurotoxic sideeffects previously seen after oral administration of comparatively low ifosfamide doses.
Key words: Ifosfamide, Activated ifosfamide, Chloroacetaldehyde, Metabolism, Pharmacokinetics
Abbreviations
- 4-OH-IF
4-hydroxyifosfamide (activated ifosfamide)
- 4-OH-CP
4-hydroxycyclophosphamide (activated cyclophosphamide)
- 7-OH-QU
7-hydroxy-quinoline
- AUC
area under thec/t curve
References
- Alarcon RA (1968) Fluorometric determination of acrolein and related compounds withm-aminophenol. Anal Chem 40:1704–1708 [DOI] [PubMed] [Google Scholar]
- Arndt AS, Balis FM, McCully CL, Colvin OM, Poplack DG (1988) Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 48:2113–2115 [PubMed] [Google Scholar]
- Brade WP, Herdrich K, Varini M (1985) Ifosfamide — pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1–47 [DOI] [PubMed] [Google Scholar]
- Cerny T, Margison JM, Thatcher N, Wilkinson PM (1986) Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol 18:261–264 [DOI] [PubMed] [Google Scholar]
- Farmer PB (1988) Enantiomers of cyclophosphamide and iphosphamide. Biochem Pharmacol 37:145–148 [DOI] [PubMed] [Google Scholar]
- Goren MP, Wright RK, Pratt CB, Pell FE (1986) Dechlorethylation of ifosfamide and neurotoxicity. Lancet 2:1219–1220 [DOI] [PubMed] [Google Scholar]
- Klein HO, Wickramanayake PD, Christian E, Coerper C (1984) Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, ASTA Z 7557). Cancer 54:1193–1203 [DOI] [PubMed] [Google Scholar]
- Küpfer A, Cerny T, Idle JR (1990) Intramolecular rearrangement of ifosfamide in aqueous solutions. Lancet 1:1461 [DOI] [PubMed] [Google Scholar]
- Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM (1989) Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 49:753–757 [PubMed] [Google Scholar]
- Morgan LR, Harrison EF, Hawke JE, Hunter HL, Costanzi JJ, Plotkin D, Tucker WG, Worall PM (1982) Toxicity of single — vs fractionated — dose ifosfamide in non small cell lung cancer: a multi-center study. Semin Oncol 9 [Suppl l]:66–70 [PubMed] [Google Scholar]
- Nelson RL, Allen LM, Creaven PJ (1976) Pharmacokinetics of divided dose ifosfamide. Clin Pharmacol Ther 19:365–370 [DOI] [PubMed] [Google Scholar]
- Norpoth K (1976) Studies on the metabolism of isophosphamide (NSC 109724) in man. Cancer Treat Rep 60:437–443 [PubMed] [Google Scholar]
- Piazza E, Cattaneo MT, Varini M (1984) Pharmacokinetic studies in lung cancer patients. Cancer 54:1187–1192 [DOI] [PubMed] [Google Scholar]
- Schuler U, Ehninger G, Wagner T (1987) Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol 20:248–252 [DOI] [PubMed] [Google Scholar]
- Sladek NE (1973) Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res 33:1150–1158 [PubMed] [Google Scholar]
- Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37:301–355 [DOI] [PubMed] [Google Scholar]
- Sladek NE, Doeden D, Powers JF, Krivit W (1984) Plasma concentrations of 4-hydroxy-cyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 68:1247–1254 [PubMed] [Google Scholar]
- Wagner T, Drings P, (1986) Pharmakokinetics and bioavailability of oral ifosfamide. Arzneimittelforschung (Drug Res) 36:878–880 [PubMed] [Google Scholar]
- Wagner T, Fenneberg K (1984) Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations. Arzneimittelforschung (Drug Res) 34:313–316 [PubMed] [Google Scholar]
- Wagner T, Peter G, Voelcker G, Hohorst HJ (1977) Characterization and quantitative estimation of activated cyclophosphamide in blood and urine. Cancer Res 37:2592–2596 [PubMed] [Google Scholar]
- Wagner T, Heydrich D, Jork T, Voelcker G, Hohorst HJ (1981) Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol 100:95–104 [DOI] [PMC free article] [PubMed] [Google Scholar]